Disclosed Amino Acid Sequence Derived From Bacterium (e.g., Mycoplasma, Anaplasma, Etc.) Patents (Class 424/190.1)
-
Patent number: 8900598Abstract: A vaccine against the Chagas disease, capable of stimulating the immune response against the trans-sialidase virulence factor of the Trypanosoma cruzi parasite, which is a multicomponent vaccine comprising: (a) an immunogenic portion formed by one or more recombinant or synthetic polypeptides or fractions of thereof and (b) one or more polynucleotides including the regions codifying one or more immunogenic polypeptides, or a monocomponent vaccine comprising at least one component selected among an immunogenic portion formed by one or more recombinant or synthetic polypeptides or fractions of them and a group of polynucleotides including the regions codifying one or more immunogenic polypeptides derived from Trypanosoma cruzi and pharmaceutical compositions containing said multicomponent and monocomponent vaccines, the procedures for obtaining the immunogen portion of said vaccines and the nucleic acid used in the procedure.Type: GrantFiled: October 30, 2008Date of Patent: December 2, 2014Inventor: Carlos de Baeremaecker Barros
-
Publication number: 20140348868Abstract: Disclosed herein are various combinations of pneumococcal polypeptides for use in immunisation. Also disclosed herein are pneumococcal polypeptides that may be useful as single antigens. These polypeptides may optionally be used in combination with pneumococcal saccharides. The antigens may be used in pneumococcal vaccines, but may also be used as components in vaccines for immunising against multiple pathogens.Type: ApplicationFiled: June 6, 2014Publication date: November 27, 2014Applicant: NOVARTIS AGInventors: Claudio DONATI, Alessandro MUZZI, Vega MASIGNANI, Fabio BAGNOLI, Paolo RUGGIERO, Michèle Anne BAROCCHI
-
Publication number: 20140348867Abstract: The disclosure provides isolated—, compositions comprising—and methods of culturing —a Brachyspira sp. Sask30446 organism. The method comprises inoculating a liquid media or solid media with a sample comprising the Brachyspira sp. Sask30446 organism and incubating the liquid media or solid media at a temperature between 25-44° C. under anaerobic conditions. Also provided is isolated Brachyspira sp. Sask30446 organism, compositions comprising Brachyspira sp. Sask30446 organism and methods and uses thereof.Type: ApplicationFiled: July 18, 2012Publication date: November 27, 2014Inventors: John Clare Samuel Harding, Janet Elizabeth Hill, Joseph Rubin, Manuel Chirino-Trejo
-
Publication number: 20140348869Abstract: The factor H binding activity of meningococcal fHBP can be uncoupled from its bactericidal sensitivity. NMR studies have identified various amino acid residues involved in the fHBP/fH interaction and one or more of these residues is modified in a fHBP to reduce or eliminate its ability to bind to fH.Type: ApplicationFiled: July 18, 2014Publication date: November 27, 2014Inventors: Lucia BANCI, Francesca CANTINI, Sara DRAGONETTI, Maria Antonietta GENTILE, Daniele VEGGI, Maria SCARSELLI, Mariagrazia PIZZA
-
Patent number: 8895019Abstract: The invention provides a method of preventing, inhibiting or reducing a P. gingivalis biofilm in a subject comprising administering to the subject a pharmaceutical composition comprising an inhibiting agent of a polypeptide that reduces or inhibits biofilm formation and/or biofilm development. Also provided are compositions useful in the prevention, inhibition or treatment of periodontal disease or P. gingivalis infection.Type: GrantFiled: July 13, 2012Date of Patent: November 25, 2014Assignee: Oral Health Australia Pty LtdInventors: Stuart Geoffrey Dashper, Eric Charles Reynolds, Paul David Veith, Ching Seng Ang
-
Patent number: 8895006Abstract: Compositions and methods for treatment of toxin poisoning are disclosed.Type: GrantFiled: March 5, 2012Date of Patent: November 25, 2014Assignee: Rutgers, The State University of New JerseyInventors: Nilgun Tumer, Xiao-Ping Li
-
Patent number: 8895030Abstract: The present disclosure relates to surface proteins of Moraxella catarrhalis and their ability to interact with epithelial cells via cell-associated fibronectin and laminin, and also to their ability to inhibit the complement system. These surface proteins are useful in the preparation of vaccines. The present disclosure also provides peptides interacting with fibronectin, laminin and the complement system.Type: GrantFiled: November 1, 2012Date of Patent: November 25, 2014Assignee: Arne Forsgren ABInventors: Arne Forsgren, Kristian Riesbeck
-
Patent number: 8895257Abstract: Chimera proteins including: (i) at least one sequence of a VlsE protein of a Borrelia species selected from B. garinii, B. burgdorferi sensu stricto and B. afzelii, and (ii) at least one sequence including sequences of the IR6 domain of B. burgdorferi sensu stricto, B. afzelii and B. garinii. Also, a method and a kit for the in vitro diagnosis of Lyme borreliosis using said proteins.Type: GrantFiled: August 27, 2010Date of Patent: November 25, 2014Assignee: BiomerieuxInventors: Lionel Levet, Odile Mejan-Letourneur
-
Publication number: 20140341943Abstract: The novel omp-1 gene cluster encoding twenty one Ehrlichia ewingii (EE) proteins was isolated and sequenced completely. This invention relates to isolated E. ewingii (EE) polypeptides, isolated polynucleotides encoding EE polypeptides, probes, primers, isolated antibodies and methods of their production, immunogenic compositions and vaccines, as well as methods of using the EE polypeptides, antibodies, probes, and primers for the purpose of diagnosis, therapy and production of vaccines against E. ewingii.Type: ApplicationFiled: June 11, 2014Publication date: November 20, 2014Applicant: The Ohio State University Research FoundationInventor: Yasuko Rikihisa
-
Publication number: 20140341944Abstract: Nucleic acid molecules which encode an MRSA PBP2a protein or a fragment thereof which comprises at least 245 amino acid are disclosed. Compositions comprising the nucleic acid molecules are disclosed. Novel proteins which comprise a MRSA PBP2a protein or a fragment thereof which comprises at least 245 amino acid are disclosed are disclosed. Methods of inducing an immune response against MRSA PBP2a are disclosed, as are methods of treating an individual who has been diagnosed with MRSA and methods of preventing MRSA infection in an individual.Type: ApplicationFiled: December 11, 2012Publication date: November 20, 2014Inventors: David B. Weiner, Matthew P. Morrow
-
Publication number: 20140341895Abstract: The present invention relates to a peptide antigens derived from Pseudomonas aeruginosa outer membrane protein OprM for use in the diagnosis of Pseudomonas aeruginosa infection and/or prevention/treatment of diseases associated with Pseudomonas aeruginosa infection. Methods of inducing an immune response to Pseudomonas aeruginosa using peptide antigens derived from the OprM outer loops as well as derivatives or fragments thereof are also encompassed by the present invention. Compositions used to practice the methods of the invention are also encompassed.Type: ApplicationFiled: December 17, 2012Publication date: November 20, 2014Inventors: Katherine Young, Francisco J. Dieguez, Ronald E. Painter
-
Publication number: 20140341942Abstract: This disclosure relates to modified Streptococcus pneumonia pneumolysm (PLY) proteins which lack hemolytic activity and can be used as immunogens in an immunogenic composition or vaccine against invasive pneumococcol diseases caused by S.Type: ApplicationFiled: May 5, 2014Publication date: November 20, 2014Inventors: Eliud Oloo, Raymond Oomen, Martina Ochs, Jeremy Yethon
-
Patent number: 8889128Abstract: The invention provides use of an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies.Type: GrantFiled: December 12, 2007Date of Patent: November 18, 2014Assignee: Hansa Medical ABInventors: Lars Björck, Mattias Collin, Arne Olsén, Rikard Holmdahl, Kutty Selva Nandakumar, Oonagh Shannon
-
Patent number: 8889142Abstract: The present invention is related to antigen from Chlamydia trachomatis which are recognized by specific antibodies from individuals infected with Chlamydia or which can induce T cells from the same individuals to secrete gamma-interferon. The T cell reactive antigens are present in a whole-cell lysate and have apparent molecular weights of 5-12, 16-20, 25-35 and 58-74 kDa as determined by SDS-PAGE. The antigens of the invention are believed to be useful in vaccines but also as diagnostic compositions.Type: GrantFiled: October 11, 2005Date of Patent: November 18, 2014Assignee: Statens Serum InstitutInventors: Michael Theisen, Anja Olsen, Robert Leah, Frank Follmann, Klaus Jensen, Peter Andersen
-
Patent number: 8889150Abstract: Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from genes expressed during Staphylococcal intramammary infection, and more particularly genes SACOL0029, SACOL0264, SACOL0442, SACOL0718, SACOL0720, SACOL1353, SACOL1416, SACOL1611, SACOL1944, SACOL2144, SACOL2365 or SACOL2599, based on the gene nomenclature from the Staphylococcus aureus COL (SACOL) genome.Type: GrantFiled: March 17, 2011Date of Patent: November 18, 2014Assignee: SOCPRA—Sciences et Génie, s.e.c.Inventors: Francois Malouin, Marianne Allard, Christian Lebeau Jacob, Brian Geoffrey Talbot, Daniel Scholl, Pierre Lacasse, Moussa Sory Diarra, Celine Ster
-
Publication number: 20140335092Abstract: The present invention provides vaccine compositions comprising OmpA, or antigenic fragments thereof, and related methods of active immunization against A. baumannii infection. The invention also provides antibodies and antigen-binding parts thereof that specifically bind to OmpA, and related methods of passive immunization against A. baumannii infection. The compositions and methods of the invention are useful for preventing or treating A. baumannii infections, including those caused by strains resistant to carbapenems and all other antibiotics except colistin or tigecycline, also referred to as extreme drug resistant (XDR) A. baumannii infections, and those resistant to every FDA approved antibiotic, also referred to as pan-drug resistant (PDR) A. baumannii infections.Type: ApplicationFiled: May 15, 2014Publication date: November 13, 2014Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Brad J. SPELLBERG, Lin LIN, Ashraf IBRAHIM, Guanpingsheng LUO
-
Publication number: 20140335121Abstract: The present invention has as its object to provide a process for determining the degree of pathogenicity of infecting bacterial strains in the case of canine periodontal disease. The present inventors found that Porphyromonas gulae is a major pathogen of canine periodontal disease, and demonstrated that the fimA genes encoding FimA (fimbrillin) protein which constitute fimbriae of this bacterium are classified into three major groups, and that each of the groups is correlated with the pathogenicity of this bacterium as a pathogenic bacterial of periodontal disease. Thus the inventors completed the present invention.Type: ApplicationFiled: December 13, 2012Publication date: November 13, 2014Inventors: Fumitoshi Asai, Yukio Kato, Mitsuyuki Shirai, Masaru Murakami, Kazuhiko Nakano, Ryota Nomura
-
Publication number: 20140335120Abstract: Provided herein are recombinant Listeria strains expressing a tumor-specific antigenic polypeptide and, optionally, an angiogenic polypeptide wherein a nucleic acid molecule encoding at least one of the polypeptides is operably integrated into the Listeria genome in an open reading frame with a nucleic acid sequence encoding a PEST-containing polypeptide, methods of preparing same, and methods of inducing an immune response, and treating, inhibiting, or suppressing cancer or tumors comprising administering same.Type: ApplicationFiled: July 25, 2014Publication date: November 13, 2014Inventors: Paulo MACIAG, Anu Wallecha, Vafa Shahabi
-
Patent number: 8883172Abstract: The invention provides processes for improving the ability of a peptide to stimulate an immune response, comprising exposing the peptide to a chemical modifying agent. It further provides compositions comprising an antigenic peptide, wherein the peptide has been treated with a chemical modifying agent to improve its ability to stimulate an immune response. It also provides methods of stimulating an immune response in a mammal, comprising administering to the mammal an effective amount of a vaccine.Type: GrantFiled: June 13, 2008Date of Patent: November 11, 2014Assignee: The Secretary of State for HealthInventors: Clifford Shone, Xiaomi Tong, Joanna Clancy, Mili Gu
-
Publication number: 20140322256Abstract: A composition and method for immunizing a mammal infected with Mycobacterium are disclosed. The genes gcpE, pstA, kdpC, papA2, impA, umaA1, fabG2_2, aceAB, mbtH2, lpqP, map0834c, cspB, lipN, and map1634 of M. paratuberculosis and the products that they encode are vaccine targets for Johne's and Crohn's disease. Eighteen M. paratuberculosis-specific genomic islands (MAPs) were identified. Three inverted large genomic fragments in M. paratuberculosis (INV) were also identified. These genomic identifiers represent novel virulence determinants that can be used as targets for vaccines and for developments of drugs against Johne's disease. The methods can be used to deliver an immunizing compound to a mammal, to provide an immune response against Johne's or Crohn's disease in the mammal.Type: ApplicationFiled: May 2, 2014Publication date: October 30, 2014Applicant: Wisconsin Alumni Research FoundationInventor: Adel Mohammed Talaat
-
Patent number: 8871214Abstract: Detoxified variants of the pathogenic E. coli ‘AcfD precursor’ (orf3526) have been identified that raise a substantially similar immune response in a subject as the native AcfD (orB526) protein. The detoxified variants may be further modified to have increased solubility as compared to the native AcfD (orf3526) protein.Type: GrantFiled: July 16, 2010Date of Patent: October 28, 2014Assignee: Novartis AGInventors: Laura Serino, Danilo Gomes Moriel, Maria Rita Fontana
-
Patent number: 8871213Abstract: The invention relates to generation and use of cellular and humoral responses for the prevention and treatment of P. gingivalis related conditions and diseases.Type: GrantFiled: August 28, 2009Date of Patent: October 28, 2014Assignee: Oral Health Australia Pty LtdInventors: Eric Charles Reynolds, Neil Martin O'Brien Simpson, Keith J Cross, Nada Slakeski
-
Patent number: 8871215Abstract: The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptsis is described.Type: GrantFiled: May 21, 2014Date of Patent: October 28, 2014Assignee: Cleveland Clinic FoundationInventors: Andrei V. Gudkov, Joseph A. DiDonato, Vadim Krivokrysenko
-
Publication number: 20140314802Abstract: The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; of (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis.Type: ApplicationFiled: May 21, 2014Publication date: October 23, 2014Applicant: GlaxoSmithKline Biologicals S.A.Inventors: Pascal METTENS, James BROWN, Dennis MURPHY
-
Publication number: 20140314803Abstract: Disclosed are compositions and methods related to vaccination for AOM and children prone to AOM.Type: ApplicationFiled: June 27, 2014Publication date: October 23, 2014Inventors: Michael Pichichero, M. Nadeem Khan, Ravinder Kaur, Sharad Sharma, Janet Casey, Lea Michel
-
Publication number: 20140314801Abstract: The instant invention provides an immunogenic composition comprising an antigenic fragment of OspA protein of Borrelia burgdorferi and a chimeric protein containing antigenic fragments of different phylotypes of OspC protein of Borrelia burgdorferi. Vaccines incorporating the immunogenic composition of the invention, as well as methods of preventing Lyme disease in dogs and/or protecting dogs from Lyme disease using the vaccines are also provided.Type: ApplicationFiled: April 17, 2013Publication date: October 23, 2014Inventors: Robert M. Lohse, Patrick F. M. Meeus, Jason J. Millership, Zhichang Xu
-
Publication number: 20140308291Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides methods of inducing an immune response against a panton-valentine leukocidin (PVL)-expressing S. aureus, methods of preventing or treating S. aureus infections, and composition for preventing or treating S. aureus infections.Type: ApplicationFiled: November 30, 2012Publication date: October 16, 2014Inventors: Mohammad Javad Aman, Rajan Prasad Adhikari, Hatice Karauzum, Jawad Sarwar, Sergey Shulenin, Sathya Venkataramani, Kelly Lyn Warfield, Tam Luong Nguyen
-
Patent number: 8858957Abstract: The invention provides mutants of GAS57 (Spy0416) which are unable to cleave IL-8 and similar substrates but which still maintain the ability to induce protection against S. pyogenes. The invention also provides antibodies which specifically bind to GAS57 and which inhibit its ability to cleave IL-8 and similar substrates. The mutants are useful, inter alia, in vaccine compositions to induce protection against S. pyogenes. The antibodies are useful, e.g., as therapeutics for treating S. pyogenes infections.Type: GrantFiled: March 14, 2013Date of Patent: October 14, 2014Assignee: Novartis AGInventors: Immaculada Margarit Y Ros, Guido Grandi, Chiara Zingaretti
-
Publication number: 20140302084Abstract: Production of protein conjugate vaccines by use of transpeptidase enzymes, such as sortase enzymes. For example, homogenous immunoconjugates (e.g., a population of molecules having the same structure) formed by conjugating an antigenic polypeptide and a bacterial capsule component are provided. In certain aspects, methods for generating an immune response to B. anthracis by use of protective antigen-PDGA immunoconjugates are provided.Type: ApplicationFiled: August 5, 2012Publication date: October 9, 2014Applicant: The University of ChicagoInventors: Olaf Schneewind, Dominique M. Missiakas, Yating Wang
-
Publication number: 20140302083Abstract: The present invention relates to isolated Porphyromanas gingivalis polypeptides and nucleotides. The polypeptides include an amino acid sequence selected from the group consisting of: SEQ. ID. NO. 110; SEQ. ID. NO. 111; SEQ. ID. NO. 112; SEQ. ID. NO. 113; SEQ ID NO: 120; SEQ. ID. NO. 123; SEQ. ID. NO. 124; SEQ. ID. NO. 125; SEQ. ID. NO. 130; SEQ. ID. NO. 131; SEQ. ID. NO. 132; SEQ. ID. NO. 133; SEQ. ID. NO. 135; SEQ. ID. NO. 136; SEQ. ID. NO. 137; SEQ. ID. NO. 138; SEQ. ID. NO. 143; SEQ. ID. NO. 144; SEQ. ID. NO. 145; SEQ. ID. NO. 146; SEQ. ID. NO. 147; SEQ. ID. NO. 148; and amino acid sequences at least 95% identical thereto.Type: ApplicationFiled: January 23, 2014Publication date: October 9, 2014Applicants: THE UNIVERSITY OF MELBOURNE, CSL LIMITEDInventors: BRUCE C. ROSS, IAN G. BARR, MICHELLE A. PATTERSON, CATHERINE T. AGIUS, LINDA J. ROTHEL, MAI B. MARGETTS, DIANNA M. HOCKING, ELIZABETH A. WEBB
-
Publication number: 20140294886Abstract: Two or more Neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula NH2-A-[-X-L-]n-B-COOH where X is an amino acid sequence, L is an optional linker amino acid sequence. A is an optional N-terminal amino acid sequence, B is an optional C-terminal amino acid sequence, and n is an integer greater than 1. Proteins where each of the n —X— moieties shares sequence identity to each other —X— moiety, the protein is a ‘tandem protein’.Type: ApplicationFiled: June 16, 2014Publication date: October 2, 2014Inventor: Mariagrazia PIZZA
-
Publication number: 20140294887Abstract: Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant.Type: ApplicationFiled: June 17, 2014Publication date: October 2, 2014Inventors: Mario CONTORNI, Lorenzo TARLI
-
Publication number: 20140294888Abstract: The present invention relates to methods of inducing an immune response to Staphylococcus comprising administering a composition comprising an SA2451-related polypeptide from Staphylococcus aureus as well as derivatives or fragments thereof. The present invention also encompasses methods of treating and/or reducing the likelihood of a Staphylococcus infection by administering a composition comprising an SA2451-related polypeptide or an antibody that specifically binds to an SA2451 polypeptide, derivative or fragments thereof. Compositions administered in the methods of the invention can include one or more additional antigens. Compositions used to practice the methods of the invention are also encompassed.Type: ApplicationFiled: October 26, 2012Publication date: October 2, 2014Inventors: Tessie McNeely, Donna Lorraine Montgomery, Leslie Cope, Amita Joshi, Gregory P. Pancari, Hongxia Fan
-
Publication number: 20140294883Abstract: The present invention is concerned with the development of a vaccine against Aeromonas hydrophila for use especially in fish. The invention provides an immunogenic S-layer protein of approximately 50 kDa of A. hydrophila for use in the development of a vaccine, as well as the nucleic acid encoding said protein and vaccines comprising said protein or nucleic acid encoding said protein.Type: ApplicationFiled: February 24, 2014Publication date: October 2, 2014Applicant: University of StirlingInventors: Saravanane POOBALANE, Kim Thompson, Alexandra Adams
-
Publication number: 20140294884Abstract: NadA, App and ORF40 function as adhesins in N. meningitidis. Adhesion nad be modulated by targeting these three proteins. NadA allelic variants are also disclosed. Autoproteolytic cleavage of App is disclosed, as is removal of the activity by mutagenesis. App is processed and secreted into culture medium when expressed in E. coli. Mature App proteins are disclosed. Knockout mutants are disclosed. Vesicles from non-Neisserial hosts with heterologous adhesion expression are disclosed.Type: ApplicationFiled: March 24, 2014Publication date: October 2, 2014Applicant: NOVARTIS VACCINES AND DIAGNOSTICS SRLInventors: Maria ARICO, Maurizio COMANDUCCI
-
Publication number: 20140294885Abstract: Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae are disclosed. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.Type: ApplicationFiled: April 3, 2014Publication date: October 2, 2014Applicant: NOVARTIS AGInventors: Maria Beatrice ARICO, Maurizio COMANDUCCI, Cesira GALEOTTI, Vega MASIGNANI, Marzia Monica GIULIANI, Mariagrazia PIZZA
-
Publication number: 20140294882Abstract: The present invention relates to protecting against, treating, and detecting Fusobacteria infections. Compositions and methods derived from nucleic acid and protein sequences of a 40 kDa Adhesin protein are provided to protect against, treat, and detect Fusobacteria infections in a subject. In one aspect, vaccines capable of inducing an immune response to a 40 kDa Adhesin protein are used to protect against Fusobacteria infection. Also, nucleic acid molecules, proteins, immunogens, antibodies, and antisense molecules derived from the sequences of the 40 kDa Adhesin protein may be used to protect against, treat, and detect Fusobacteria infections in a subject.Type: ApplicationFiled: March 26, 2012Publication date: October 2, 2014Applicant: KANSAS STATE UNIVERSITY RESEARCH FOUNDATIONInventors: Sanjeev Narayanan, Amit Kumar, Tiruvoor Nagaraja, Muckatira Chengappa
-
Publication number: 20140294881Abstract: The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants, as well as methods for making proteins less allergenic. In addition, the present invention provides various compositions that comprise these proteins that are less immunogenic than the wild-type proteins.Type: ApplicationFiled: September 18, 2008Publication date: October 2, 2014Applicant: Danisco US Inc.Inventors: David A. Estell, Fiona A. Harding, Ayrookaran J. Poulose
-
Patent number: 8846342Abstract: The invention is directed to bioconjugate vaccines comprising N-glycosylated proteins. Further, the present invention is directed to a recombinant prokaryotic biosynthetic system comprising nucleic acids encoding an epimerase that synthesizes an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus. The invention is further directed to N-glycosylated proteins containing an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus and an expression system and methods for producing such N-glycosylated proteins.Type: GrantFiled: November 16, 2010Date of Patent: September 30, 2014Assignee: GlycoVaxyn AGInventors: Michael Wacker, Charles Waechter
-
Publication number: 20140286986Abstract: Isolated polypeptides are provided that comprise a cholera toxin B subunit variant having one or more modifications to increase the expression of the polypeptide in a plant cell. Nucleic acids sequences, vectors, and plant cells for expressing the cholera toxin B subunit variant polypeptides are also provided. Further provided are methods for producing the cholera toxin B subunit variant polypeptides that include the steps of transforming a plant cell with a nucleic acid encoding the cholera toxin B subunit variant polypeptides; expressing the variant polypeptides; and purifying the polypeptides. Still further provided are methods of isolating the variant polypeptides that include the steps of obtaining a plant cell expressing the cholera toxin B subunit variant polypeptides; extracting the cholera toxin B subunit variant polypeptides from the plant cell; and purifying the cholera toxin B subunit variant polypeptides. Methods of eliciting an immune response are also provided.Type: ApplicationFiled: March 14, 2012Publication date: September 25, 2014Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: Nobuyuki Matoba, Krystal Hamorsky
-
Patent number: 8840901Abstract: The present invention relates to the use of Yersinia outer protein M (YopM), a YopM fragment, or a YopM variant, which is capable of autopenetrating the cell membrane and of integrating into the cell cytosol without the requirement of additional factors for delivering a cargo molecule across the membrane to the cytosol of a cell. The present invention also relates to a pharmaceutical composition comprising YopM, a YopM fragment, or a YopM variant being capable of autopenetrating the cell membrane and of integrating into the cell cytosol without the requirement of additional factors for the regulation of inflammatory reactions of the immune system and the treatment of diseases caused by autoimmunity of the host. The present invention further relates to a YopM fragment or variant, which is capable of autopenetrating the cell membrane and of integrating into the cell cytosol without the requirements of additional factors as well as such proteins or YopM linked to a cargo molecule.Type: GrantFiled: March 17, 2009Date of Patent: September 23, 2014Assignee: Universitaetsklinikum MuensterInventors: Christian Rüter, Gerhard Heusipp, Alexander M. Schmidt
-
Patent number: 8841416Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.Type: GrantFiled: August 3, 2011Date of Patent: September 23, 2014Assignee: University of WashingtonInventors: Jeffrey A. Ledbetter, Martha Hayden-Ledbetter, Keith Elkon, Xizhang Sun
-
Publication number: 20140271701Abstract: The present invention concerns antibodies recognizing Mycobacterium avium paratuberculosis epitopes able to cross-reacting with the beta-cell antigen ZnT8 to be used as early biomarkers of type 1 diabetes, epitopes for in vitro prognostic and diagnostic methods suitable to reveal a risk to develop type 1 diabetes, therapies for the prevention of T1D by avoiding, controlling or monitoring Mycobacterium paratuberculosis infection.Type: ApplicationFiled: October 25, 2012Publication date: September 18, 2014Inventors: Leonardo Antonio Sechi, Roberto Mallone
-
Publication number: 20140271700Abstract: Described herein are isolated polypeptides each containing one or more receptor-binding sites of toxin A (tcdA) of Clostridium difficile (Cd), nucleic acids encoding the polypeptides, and methods of using the polypeptides and nucleic acids.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: National Health Research InstitutesInventors: Pele Choi-Sing Chong, Jui-Hsin Huang, Chih-Hsiang Leng
-
Patent number: 8834898Abstract: The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of an antigenic material from S. aureus and an antigenic material from a S. aureus-specific polypeptide.Type: GrantFiled: December 16, 2011Date of Patent: September 16, 2014Assignee: Boise State UniversityInventor: Juliette Tinker
-
Publication number: 20140255441Abstract: This disclosure relates to immunogenic compositions and methods of enhancing an immune response to an antigen. In certain embodiments, the disclosure relates to virus-like carries comprising a TLR5 agonist on the exterior without an antigen.Type: ApplicationFiled: July 31, 2012Publication date: September 11, 2014Applicants: CHILDREN'S HEATLHCARE OF ATLANTA, INC., EMORY UNIVERSITYInventors: Richard W. Compans, Baozhong Wang, Martin L. Moore, Fu Shi Quan
-
Publication number: 20140255416Abstract: Disclosed are polypeptides for Campylobacter jejuni that are useful as immungenic agents for vaccine use. Also disclosed are nucleic acid fragments encoding the polypeptides as well as compositions, methods and molecular biology tools derived from or related to the proteins.Type: ApplicationFiled: October 12, 2012Publication date: September 11, 2014Inventors: Niels Iversen Møller, Andreas Mattsson
-
Publication number: 20140255443Abstract: The invention provides methods of treating subject with polypeptides having at least 80% identity to SEQ ID NO: 5326. The methods stimulate an immune response in the subject and provide methods for prevention and treatment of pathological conditions resulting from bacterial infection.Type: ApplicationFiled: December 5, 2013Publication date: September 11, 2014Applicant: Sanofi Pasteur Limited/Sanofi Pasteur LimiteeInventors: Lynn Doucette-Stamm, David Bush, Qiandong Zeng, Timothy Opperman, Chad Eric Houseweart
-
Publication number: 20140248273Abstract: The present invention relates to the field of vaccinology, especially of vaccines against Staphylococcus aureus, for both human and veterinary application. In particular the invention relates to a Staphylococcal superantigen-like 3 (SSL3) protein or its homolog, an immunogenic fragment of either protein, for use in a vaccine against S. aureus. In addition the invention relates to vaccines, methods, and medical uses of these proteins.Type: ApplicationFiled: September 7, 2012Publication date: September 4, 2014Inventors: Jos van Strijp, Carla de Haas, Paul Vermeij, Bart Bardoel
-
Publication number: 20140248302Abstract: A recombinant protein expressing one or more human growth factors, tumor antigens, and/or receptors or epitopes thereof on or within an immunogenic expression creating a recombinant protein in which one or more epitopes are presented on the surface of the sequence in their natural configuration. The growth factor, tumor antigen, and/or receptor, sequence(s) may be expressed within the encoding sequence at appropriate internal positions or at the termini as single expressions or as two or more tandem repeats.Type: ApplicationFiled: November 21, 2012Publication date: September 4, 2014Applicant: BIOVEN 3 LIMITEDInventors: Keith Alan Charlton, Erik D'Hondt